Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
Go back to Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1| (NASDAQ: BLTE) | Delayed: 147.07 +0.95 (0.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.12 | 52 Week High | $ | |||
| Open | $147.63 | 52 Week Low | $ | |||
| Day High | $150.00 | P/E | N/A | |||
| Day Low | $144.79 | EPS | $ | |||
| Volume | 172,446 | |||||
